DE602005025897D1 - Verfahren und zusammensetzungen in verbindung mit morbus alzheimer - Google Patents

Verfahren und zusammensetzungen in verbindung mit morbus alzheimer

Info

Publication number
DE602005025897D1
DE602005025897D1 DE602005025897T DE602005025897T DE602005025897D1 DE 602005025897 D1 DE602005025897 D1 DE 602005025897D1 DE 602005025897 T DE602005025897 T DE 602005025897T DE 602005025897 T DE602005025897 T DE 602005025897T DE 602005025897 D1 DE602005025897 D1 DE 602005025897D1
Authority
DE
Germany
Prior art keywords
alzheimer
disease
compositions
connection
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005025897T
Other languages
English (en)
Inventor
Jules Westbrook
Helen Byers
Malcolm Ward
Simon Lovestone
Abdul Hye
Stephen Lynham
Richard Joubert
Petra Prefot
Karsten Kuhn
Christian Baumann
Juergen Schaefer
Thorsten Prinz
Stefan Kienle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Proteome Sciences PLC
Original Assignee
Kings College London
Proteome Sciences PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London, Proteome Sciences PLC filed Critical Kings College London
Publication of DE602005025897D1 publication Critical patent/DE602005025897D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
DE602005025897T 2004-09-29 2005-09-29 Verfahren und zusammensetzungen in verbindung mit morbus alzheimer Active DE602005025897D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0421639.6A GB0421639D0 (en) 2004-09-29 2004-09-29 Methods and compositions relating to alzheimer's disease
PCT/GB2005/003756 WO2006035237A2 (en) 2004-09-29 2005-09-29 Methods and compositions relating to alzheimer's disease

Publications (1)

Publication Number Publication Date
DE602005025897D1 true DE602005025897D1 (de) 2011-02-24

Family

ID=33397455

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005025897T Active DE602005025897D1 (de) 2004-09-29 2005-09-29 Verfahren und zusammensetzungen in verbindung mit morbus alzheimer

Country Status (10)

Country Link
US (2) US7897361B2 (de)
EP (3) EP1794594B1 (de)
JP (3) JP5483816B2 (de)
AT (1) ATE495445T1 (de)
AU (1) AU2005288689B2 (de)
CA (1) CA2580532C (de)
DE (1) DE602005025897D1 (de)
DK (1) DK2354795T3 (de)
GB (1) GB0421639D0 (de)
WO (1) WO2006035237A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
GB0426859D0 (en) * 2004-12-07 2005-01-12 Proteome Sciences Plc Diagnosis of neurodegenerative disorders
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
EP1937815B1 (de) 2005-09-13 2015-05-13 National Research Council of Canada Verfahren und zusammensetzungen zur modulation der tumorzellaktivität
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AU2009295357A1 (en) * 2008-09-26 2010-04-01 The University Of Melbourne Alzheimer's disease biomarkers
IT1392551B1 (it) * 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
JP5755149B2 (ja) * 2009-01-26 2015-07-29 エレクトロフォレティクス リミテッドＥｌｅｃｔｒｏｐｈｏｒｅｔｉｃｓ Ｌｉｍｉｔｅｄ 方法
JP2010271078A (ja) * 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
CA2709621A1 (en) * 2009-09-11 2011-03-11 Electrophoretics Limited Markers and methods relating to the assessment of alzheimer's disease
DK2504363T3 (da) 2009-11-24 2019-07-29 Alethia Biotherapeutics Inc Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP5906519B2 (ja) * 2011-09-13 2016-04-20 国立大学法人 熊本大学 二次元電気泳動による蛋白質の分離方法
WO2013074861A1 (en) * 2011-11-18 2013-05-23 Alnylam Pharmaceuticals, Inc. Quantification of transthyretin and its isoforms
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
CA2868777A1 (en) 2012-03-29 2013-10-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Nanoscale process to generate reagents selective for individual protein variants
USRE49625E1 (en) 2012-03-29 2023-08-29 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Nanoscale process to generate reagents selective for individual protein variants
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
CA2877975C (en) 2012-04-13 2021-09-21 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
WO2014040042A2 (en) 2012-09-10 2014-03-13 The Johns Hopkins University Diagnostic assay for alzheimer's disease
WO2014055683A1 (en) * 2012-10-03 2014-04-10 The Research Foundation For The State University Of New York Spectroscopic method for alzheimer's disease diagnosis
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
JP6416793B2 (ja) * 2013-02-28 2018-10-31 カプリオン プロテオミクス インコーポレーテッド 結核のバイオマーカー及びその使用
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
GB201310203D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
GB201310150D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Methods and compositions relating to alzheimer's disease
AU2014311258B2 (en) * 2013-08-27 2020-12-17 Crc For Mental Health Ltd Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases
GB201322094D0 (en) 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
US20160327572A1 (en) * 2014-01-06 2016-11-10 Children's Medical Center Corporation Biomarkers for Dementia and Dementia Related Neurological Disorders
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
US10639322B2 (en) * 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US9904961B2 (en) 2015-05-07 2018-02-27 Kuwait University System and method for determining the feedback capacity of information distributed in a complex network
JP6193942B2 (ja) * 2015-09-09 2017-09-06 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
CN105403649B (zh) * 2015-12-01 2018-03-20 深圳大学 一种检测ad的尿液多肽组ad生物标记物
JP6947451B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
JP6947450B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
JPWO2019013341A1 (ja) * 2017-07-14 2020-07-09 株式会社Ｍｃｂｉ 疾患検出方法
JP6408087B2 (ja) * 2017-07-25 2018-10-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
CN113024651A (zh) * 2019-12-25 2021-06-25 中国医学科学院药物研究所 阿尔茨海默病生物标志物及其应用
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
WO2024083822A1 (en) * 2022-10-18 2024-04-25 Immungenetics Ag Identifying a subject suffering from alzheimer's dementia or being at risk of developing alzheimer's dementia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6342350B1 (en) * 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
US20030211622A1 (en) 1998-06-29 2003-11-13 Roberts L. Jackson Methods and compositions to assess oxidative brain injury
US20030131364A1 (en) 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
JP2001249128A (ja) * 2000-03-06 2001-09-14 Ikagaku:Kk 動脈硬化症またはアルツハイマー病の診断用キット
US20020174447A1 (en) 2001-01-23 2002-11-21 Greenspan Ralph J. Method for functional mapping of an alzheimer's disease gene network and for identifying therapeutic agents for the treatment of alzheimer's disease
US6528309B2 (en) * 2001-03-19 2003-03-04 The Regents Of The University Of California Vacuum-mediated desiccation protection of cells
US6451547B1 (en) * 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
DE10158180A1 (de) * 2001-11-28 2003-09-11 Biovision Ag Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
WO2004001421A2 (en) * 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
WO2004005462A2 (en) * 2002-07-03 2004-01-15 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of tumor senescence genes
CA2500652A1 (en) * 2002-10-02 2004-04-15 Dmi Biosciences, Inc. Diagnosis and monitoring of diseases
WO2004074837A1 (en) * 2003-02-24 2004-09-02 Digitalbiotech Co., Ltd. Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer’s disease using same
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease

Also Published As

Publication number Publication date
DK2354795T3 (en) 2015-02-16
EP2562545A1 (de) 2013-02-27
CA2580532C (en) 2019-06-25
WO2006035237A3 (en) 2006-08-03
GB0421639D0 (en) 2004-10-27
JP5893269B2 (ja) 2016-03-23
EP1794594A2 (de) 2007-06-13
US20080070995A1 (en) 2008-03-20
JP5483816B2 (ja) 2014-05-07
EP1794594B1 (de) 2011-01-12
WO2006035237A2 (en) 2006-04-06
JP2011209291A (ja) 2011-10-20
US20110165146A1 (en) 2011-07-07
EP2354795B1 (de) 2014-12-17
CA2580532A1 (en) 2006-04-06
AU2005288689A1 (en) 2006-04-06
JP2014209132A (ja) 2014-11-06
AU2005288689B2 (en) 2011-10-27
EP2354795A1 (de) 2011-08-10
JP2008514946A (ja) 2008-05-08
US7897361B2 (en) 2011-03-01
ATE495445T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
DE602005025897D1 (de) Verfahren und zusammensetzungen in verbindung mit morbus alzheimer
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
CY2015025I2 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
WO2009149486A3 (en) Compounds for treating beta-amyloidoses
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006058868A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
EP1841426A4 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
ZA200702318B (en) Nanobodies against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neual diseases such as alzheimer's disease
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
CY1110401T1 (el) Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
PT1606233E (pt) Derivados de esteres lipidicos de nucleotidos